冠状动脉粥样硬化性心脏病(coronary atherosclerotic heart disease,CHD,简称冠心病)是心血管系统中最常见的疾病之一,近年来,随着城市中人们工作压力的增加、生活作息的不规律以及人口老龄化的加剧,冠心病的发病率正在逐年上升。如今临床上冠心病的诊断主要依靠冠状动脉造影,经皮冠状动脉介入治疗(percutaneous coronary intervention,PCI)成为了冠心病的主要治疗方式；其中,冠状动脉分叉病变(coronary bifurcation lesion,CBL)占所有经皮冠状动脉介入治疗的15%~20%_^[1]。近几年来,随着我国医疗水平不断发展和科学的不断的进步,使得冠状动脉分叉病变的治疗不仅仅局限于支架治疗,药物涂层球囊(drug coated ballon,DCB)已经作为一种新的介入治疗技术已经应用在了分叉病变治疗中,但是,冠状动脉分叉病变的处理依旧充满了挑战,分叉病变的治疗效果仍然不是很理想。

Coronary atherosclerotic heart disease is one of the most common diseases in the cardiovascular system. In recent years, with the increase of work pressure, the irregularity of daily life and the aging of the population in cities, the incidence of coronary heart disease is increasing year by year. Clinically, coronary angiography is the gold standard for the diagnosis of coronary heart disease, and percutaneous coronary intervention (percutaneouscoronaryintervention,PCI) has become the main treatment for coronary heart disease; among them, coronary artery bifurcation disease (coronarybifurcationlesion,CBL) accounts for 15%~20% of all percutaneous coronary intervention_^[1]. In recent years, with the continuous development of medical level and scientific progress in our country, the treatment of coronary bifurcation lesions is not limited to stent therapy. Drug-coated balloon (drugcoatedballon,DCB) has been used in the treatment of bifurcation lesions as a new interventional technology. However, the treatment of bifurcation lesions is still full of challenges, and the therapeutic effect of bifurcation lesions is still not very ideal.